Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

FOXBOROUGH, MA. — As the New England Patriots place the finishing touches on their game plan for a Week 17 showdown against the New York Jets at MetLife Stadium, they may have the services of a highly ...

In the era of A.I. agents, many Silicon Valley programmers are now barely programming. Instead, what they’re doing is deeply, deeply weird. Credit...Illustration by Pablo Delcan and Danielle Del Plato ...

Across industries, pricing strategies are quietly shifting. What was once a predictable rhythm of annual increases is now giving way to continuous, incremental adjustments—and, in some cases, fully ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

C. Jarrett Dieterle is a legal policy fellow at the Manhattan Institute. On his way to winning the New York mayoral race, Zohran Mamdani announced his “Game Over Greed” campaign calling on FIFA to ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

When Apple introduced the new iPhone 17 and iPhone 17 Pro/Max, it highlighted their even faster fast-charging abilities. With an appropriate USB-C charger that can deliver at least 40 watts, it can ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. The analyst who called NVIDIA in 2010 just named his top ...